» Articles » PMID: 34857730

Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage

Abstract

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.

Citing Articles

Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria.

Martino E, Mele G, Vigna E, Morabito F, Gentile M Mediterr J Hematol Infect Dis. 2025; 17(1):e2025006.

PMID: 39830800 PMC: 11740893. DOI: 10.4084/MJHID.2025.006.


Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts).

Testa U, Leone G Mediterr J Hematol Infect Dis. 2025; 17(1):e2025005.

PMID: 39830797 PMC: 11740910. DOI: 10.4084/MJHID.2025.005.


Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.

Merz M, Albici A, von Tresckow B, Rathje K, Fenk R, Holderried T Hemasphere. 2025; 9(1):e70070.

PMID: 39822585 PMC: 11735948. DOI: 10.1002/hem3.70070.


MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.

Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M Hematol Oncol. 2025; 43(1):e70036.

PMID: 39804194 PMC: 11727818. DOI: 10.1002/hon.70036.


Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report.

Bernardi C, Beauverd Y, Tran T, Maulini M, Mappoura M, Morin S Front Immunol. 2024; 15:1495233.

PMID: 39676854 PMC: 11638231. DOI: 10.3389/fimmu.2024.1495233.


References
1.
Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C . Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016; 34(18):2125-32. DOI: 10.1200/JCO.2015.63.1929. View

2.
Blade J, Kyle R . Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 2000; 13(6):1259-72. DOI: 10.1016/s0889-8588(05)70125-8. View

3.
Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis M . Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. Am J Hematol. 2013; 89(2):145-50. DOI: 10.1002/ajh.23600. View

4.
Jurczyszyn A, Radocha J, Davila J, Fiala M, Gozzetti A, Grzasko N . Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018; 180(6):831-839. DOI: 10.1111/bjh.15092. View

5.
Vagnoni D, Travaglini F, Pezzoni V, Ruggieri M, Bigazzi C, Dalsass A . Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics. Br J Haematol. 2015; 170(4):523-31. DOI: 10.1111/bjh.13484. View